Cytotoxicity Profiling and IC₅₀ Determination of Madecassoside-Loaded Ultra-Small Unilamellar Nanocarrier System on Keloid-derived fibroblast cell lines: an MTT Assay and Cell Viability AnalysisViability Analysis.
Objective: To evaluate the in vitro cytotoxicity of a madecassoside-loaded ultra-small unilamellar nanocarrier system (MU) against keloid-derived fibroblasts and to compare it with that of the empty carrier and pure madecassoside. Design: In vitro experimental study using keloid-derived fibroblasts and the MTT colorimetric assay; each treatment was performed in triplicate. Intervention: MU, prepared from virgin coconut oil (VCO), soy lecithin and Tween 80 by sonication-aided emulsification, its empty carrier and pure madecassoside were applied to the cells at 10, 20, 30 and 40 µg/mL for 72 h. Main outcome measures: Cell viability (percentage of untreated control), the half-maximal inhibitory concentration (IC50) calculated by semilogarithmic linear regression, and cell morphology under an inverted microscope. Groups were compared by two-way ANOVA with Bonferroni post hoc test. Results: MU reduced fibroblast viability in a concentration-dependent manner, with an IC50 of 29.77 µg/mL compared with 58.21 µg/mL for the empty carrier and 78.80 µg/mL for pure madecassoside (the latter two extrapolated beyond the highest tested concentration). At 30 µg/mL, viability after MU treatment was significantly lower than after pure madecassoside (65.1% vs 104.4%; p < 0.05). MU was the only sample that reduced viability below 50% within the tested range. Conclusion: Loading madecassoside into the ultra-small unilamellar nanocarrier increased its cytotoxic potential against keloid fibroblasts, as reflected by an approximately 2.6-fold lower IC50 than that of pure madecassoside, with the carrier itself contributing partly to this effect. Keywords: madecassoside; ultra-small unilamellar nanocarrier; keloid fibroblast; MTT assay; IC50; cytotoxicity
Authors
- Henny Lucida (ORCID: https://orcid.org/0000-0002-1816-990X)
- Tommy Julianto
- Ully Chairunisa (ORCID: https://orcid.org/0009-0008-8946-2389)
- Hendriati Hendriati (ORCID: https://orcid.org/0000-0001-9172-9558)
Publication Details
- Journal
- Journal of Drug Delivery and Therapeutics
- Published
- 2026-11-15
- DOI
- https://doi.org/10.22270/jddt.v16i11.8092
- Primary Topic
- Advancements in Transdermal Drug Delivery
- Type
- article
- Field-Weighted Citation Impact
- 0.00